Long‐term treatment of systemic lupus erythematosus with cyclosporin A

Abstract

Objective. To evaluate the efficacy of long-term treatment with cyclosporin A (CSA) in systemic lupus erythematosus (SLE).Methods. Thirty patients with SLE whose condition was either poorly responsive or unresponsive to treatment with steroids and/or cytotoxic drugs were enrolled in a prospective, nonrandomized study of CSA. Patients with hypertension or hypercreatinemia were excluded. Disease activity was evaluated according to the systemic lupus activity measure. Assessments were made prior to study entry and after 6, 12, 18, and 24 months.Results. Twenty-seven patients completed at least 24 months of treatment with CSA. The mean disease activity score significantly decreased after 6 months of therapy (P < 0.01); this result was maintained throughout the study. A conspicuous steroid-sparing effect was observed following administration of CSA (P < 0.01).Side effects included hypertrichosis (63% of patients), paresthesias (23%), gastrointestinal symptoms (ZWo), gingival hyperplasia (17%), hypertension (lWo), tremors (7%), and nephrotoxicity (13%). No significant changes in serum creatinine levels were observed.Conclusion. CSA represents a helpful secondchoice treatment for patients with active SLE. Administration of CSA necessitates expert and careful followup of patients.Systemic lupus erythematosus (SLE), particularly in its severe form, still represents a major therapeutic Supported in part by a grant from Minister0

Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study

“…Treatment of SLE with cyclosporine, which has the same mechanism of action as tacrolimus (inhibition of calcineurin activity), has also been reported. Caccavo et al [20] found that combined cyclosporine and corticosteroid therapy was effective for skin symptoms, arthritis, and serositis in 30 SLE patients, but a number of adverse drug reactions occurred. There have been other reports about that effectiveness of cyclosporine for mild symptoms of SLE [21][22][23][24][25], but the incidence of adverse drug reactions seems to be high (40-60%).…”

Stevens–Johnson syndrome induced by mizoribine in a patient with systemic lupus erythematosus

“…2 Thus, in a young woman who wants to get pregnant, we approach cyclophosphamide therapy with some hesitancy. Other relevant drugs, such as mizoribine, 3 CyA, 4 and mycophenolate mofetil, 5 have been reported to be effective for lupus nephritis, with mizoribine often being used as it is believed to be relatively safe.…”

Effective Treatment with Cyclosporine A of a Child with Systemic Lupus Erythematosus Resistant to Cyclophosphamide Pulse Therapy

“…Caccavo et al (1997) reported on the efficacy of CsA in 30 patients with refractory SLE, including 11 IVCYresistant patients. They reported a siginificant decrease of the mean disease activity score following the initiation of CsA administration in these cases, which allowed a significant reduction of the PSL dose.…”